Cefazolin

Generic Name: Cefazolin

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₁₄N_₈O_₄S_₃

CAS Number: 25953-19-9

Unique Ingredient Identifier: IHS69L0Y4T

Background: A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.

Indication: Mainly used to treat bacterial infections of the skin. It can also be used to treat moderately severe bacterial infections involving the lung, bone, joint, stomach, blood, heart valve, and urinary tract. It is clinically effective against infections caused by staphylococci and streptococci species of Gram positive bacteria. May be used for surgical prophylax...

Associated Conditions: Bacterial Septicemia caused by susceptible Bacterial Infections, Biliary tract infection bacterial caused by susceptible Bacterial Infections, Bone and Joint Infections caused by susceptible Bacterial Infections, Catheter-related Bloodstream Infection (CRBSI) NOS, Community Acquired Pneumonia (CAP), Endocarditis caused by susceptible Bacterial Infections, Genital infection caused by susceptible Bacterial Infections, Osteoarticular Infections, Postoperative Infections, Respiratory Tract Infection Bacterial caused by susceptible Bacterial Infections, Skin and Soft Tissue Infections (SSTIs), Skin and Subcutaneous Tissue Infection caused by susceptible Bacterial Infections, Susceptible infections, Urinary Tract Infection caused by susceptible Bacterial Infections, Perioperative infection, Susceptible Bacterial Infections

Associated Therapies: Antibiotic pre-surgical prophylaxis

Clinical Trials

Postoperative Antibiotics Following Primary and Secondary Breast Augmentation

Phase 4

Withdrawn

Conditions: Surgical Site Infection
Capsular Contracture Associated With Breast Implant
Antibiotic Resistant Infection
Antibiotic Side Effect

Interventions: Drug: Cefazolin
Drug: Cephalexin
Other: Placebo

First Posted Date: 2021-04-08

Last Posted Date: 2022-09-14

Lead Sponsor: University of California, Los Angeles

Registration Number: NCT04834310

DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia

Phase 2

Completed

Conditions: Staphylococcal Bacteraemia

Interventions: Drug: Dalbavancin
Drug: Cefazolin
Drug: Daptomycin
Drug: Nafcillin
Drug: Oxacillin
Drug: Vancomycin

First Posted Date: 2021-03-01

Last Posted Date: 2024-12-10

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 200

Registration Number: NCT04775953

Locations: 🇺🇸
Corewell Health - Infectious Disease, Royal Oak, Michigan, United States
🇺🇸
University of Alabama Hospital - Infectious Diseases, Birmingham, Alabama, United States
🇺🇸
University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States

and more 21 locations

A Randomized, Controlled Trial of the Effectiveness of Perioperative Antibiotics for Reduction of Burn Wound Bacterial Concentration Following Grafting

Phase 4

Completed

Conditions: Burn
Surgery
Infection Wound

Interventions: Drug: Cefazolin
Drug: Clindamycin

First Posted Date: 2020-08-18

Last Posted Date: 2022-08-26

Lead Sponsor: Medstar Health Research Institute

Target Recruit Count: 32

Registration Number: NCT04516148

Locations: 🇺🇸
MedStar Washington Hospital Center, Washington, District of Columbia, United States

Is Cefazolin, Ceftazidime and Ciprofloxacin Dosing Optimal in Hemodialysis Patients?

Completed

Conditions: End Stage Renal Disease
Hemodialysis Complication
Infectious Disease

Interventions: Drug: Cefazolin
Drug: Ceftazidime

First Posted Date: 2020-03-24

Last Posted Date: 2024-05-16

Lead Sponsor: University of Manitoba

Target Recruit Count: 40

Registration Number: NCT04319328

Locations: 🇨🇦
College of Pharmacy, University of Manitoba, Winnipeg, Manitoba, Canada
🇨🇦
Saint Boniface Hospital, Outpatient Hemodialysis Unit, Winnipeg, Manitoba, Canada